Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.55 |
| ▸ | ICMT | O60725 | 9/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859902 | 1.00 | ADAM17 (0.55) | ADAM17ICMTKMT2AALDH1A1MAPT | |
| SCHEMBL3855663 | 0.88 | HTR6 (0.57) | ADAM17ICMTKMT2AALDH1A1MAPT | |
| SCHEMBL3855666 | 0.88 | HTR6 (0.57) | ADAM17ICMTKMT2AALDH1A1MAPT | |
| SCHEMBL3849405 | 0.88 | ADAM17 (0.54) | ADAM17ICMTKMT2AALDH1A1LMNA | |
| SCHEMBL3858061 | 0.87 | ICMT (0.53) | ADAM17ICMTKMT2AALDH1A1MAPT | |
| SCHEMBL3849402 | 0.86 | ADAM17 (0.63) | ADAM17ICMTKMT2AALDH1A1LMNA | |
| SCHEMBL3849409 | 0.86 | ADAM17 (0.63) | ADAM17ICMTKMT2AALDH1A1LMNA | |
| SCHEMBL11033128 | 0.85 | KMT2A (0.69) | KMT2AALDH1A1MAPTRECQLLMNA | |
| SCHEMBL9584445 | 0.85 | KMT2A (0.69) | KMT2AALDH1A1MAPTRECQLLMNA | |
| SCHEMBL13819344 | 0.84 | ADAM17 (0.55) | ADAM17ICMTKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576222-B2 | N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | ADAM17, TPSAB1, ADAM10 | ADAM17 1/4885ICMT 3225/4885KMT2A 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.